Autoimmune Drugs Market by Therapy Area, Distribution Channel, and Geography - Forecast and Analysis 2023-2027
| Published: Jan 2023 | Pages: 173 | SKU: IRTNTR70662 |
Autoimmune Drugs Market Analysis Report 2023-2027 :
The autoimmune drugs market size is estimated to grow at a CAGR of 6.39% between 2022 and 2027. The autoimmune drug market size forecast is set to increase by USD 29,314.5 million. The growth of the market depends on several factors, including a strong R&D pipeline, a targeted therapeutic mechanism of biologics, and the introduction of affordable biosimilars.
This autoimmune drug market report extensively covers market segmentation by therapy area (rheumatoid arthritis, multiple sclerosis, psoriasis, inflammatory bowel disease, and others), distribution channel (hospital, pharmacy, drug store/retail pharmacy, and online), and geography (North America, Europe, Asia, and Rest of World (ROW). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
What will be the size of the Autoimmune Drugs Market Report During the Forecast Period?
To learn more about this report, Download Autoimmune Drug Market Research Report Sample Pdf
Autoimmune Drugs Market: Key Drivers, Trends, Challenges, and Customer Landscape
The introduction of affordable biosimilars is notably driving the market growth, although factors such as the high cost of biologics may impede the market growth. Our researchers analyzed the data with 2022 as the base year and the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Key Autoimmune Drugs Market Driver
The introduction of affordable biosimilars is notably driving market growth. Biologics used to treat autoimmune disorders are expensive, thus, they become unaffordable for the majority of patients. As a solution to the high cost of biologics, biosimilars are emerging as affordable therapies. Biosimilars are called follow-on biologics and are similar but not identical to biologics. They are priced 20%-25% less than originator biologics.
The number of clinical trials required for the approval of biosimilars is comparatively less than biologics, this directly reduces the cost of biologics. In addition, biosimilars do not have any post-marketing R&D costs or any marketing or market access expenses, because of which they are less expensive than biologics. The lower price of biosimilars compared with originator biologics is attracting healthcare providers to provide reimbursement for them. Thus, the introduction of biosimilars has increased access to advanced treatment options for patients with autoimmune disorders. Therefore, such factors will drive the autoimmune disease therapeutics market growth during the forecast period.
Significant Autoimmune Drugs Market Trends
The market dominance by TNF-alpha inhibitors is an emerging trend in the autoimmune disease therapeutics market. The global market is dominated by TNF-alpha inhibitors that are very effective as they target specific receptors on the cell surface. Some of the widely sold TNF-alpha inhibitors are HUMIRA, Enbrel, Cimzia, and SIMPONI, which are routinely prescribed as a first line of treatment for the management of autoimmune disorders, mainly rheumatoid arthritis, psoriasis, and multiple sclerosis.
Moreover, several efforts are being made to introduce a different class of drugs for autoimmune diseases. Some of the emerging drugs include the JAK kinase inhibitors that target the JAK kinase protein, a mechanism different from those of TNF-alpha inhibitors. Some of the marketed products under this category include XELJANZ and ACTEMRA. It is expected that in the future, they will have the potential to even replace some of the TNF-alpha inhibitors. Hence, such developments will boost the growth of the market in focus during the forecast period.
Major Autoimmune Drugs Market Challenge
The high cost of biologics is a major challenge impeding market growth. For autoimmune diseases, the therapeutic benefits offered by biologics outweigh the benefits of small molecules. Biologics not only have a targeted action but also have minimal side effects. However, the biggest challenge is the high cost of these miraculous therapies. Manufacturers continue to keep high prices for these treatments and state that manufacturing costs and clinical trials associated with biologics are responsible for the heavy price tags of biologics.
Biologics are manufactured by using living organisms. The production of biologics using bacterial systems is economical, but when monoclonal antibodies are used, the production costs more. The production of monoclonal antibodies requires immunization procedures to be done in animals such as rabbits, rats, and guinea pigs, which are among the most important process in research and the costliest ones. Also, separate animal house facilities for raring animals, skilled labor, and government approvals for sacrificing animals add up to the cost of biologics. Due to high costs, the majority of patients with autoimmune diseases, mainly in developing nations, cannot afford biologics. Hence, these factors will hinder the market growth prospects during the forecast period.
Key Autoimmune Drugs Market Customer Landscape
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Autoimmune Drugs Market Customer Landscape
Who are the Major Autoimmune Drugs Market Vendors?
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc. - The company offers conducts R&D, manufacturing, commercialization, and sale of innovative medicines and therapies to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. The key offerings of the company include autoimmune drugs.
The autoimmune drug market research report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
- AdvaCare Pharma
- Amgen Inc.
- AstraZeneca Plc
- Bristol Myers Squibb Co.
- Cardinal Health Inc.
- Delphis Pharmaceutical India
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Hikma Pharmaceuticals Plc
- Johnson and Johnson
- Medexus Pharmaceuticals Inc.
- Parvus Therapeutics Inc.
- Prometheus Laboratories Inc.
- Regeneron Pharmaceuticals Inc.
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
Parent Market Analysis
Technavio categorizes the as a part of the global autoimmune drugs market within the overall healthcare industry. The parent global pharmaceuticals market covers products and companies engaged in R&D or the production of generic drugs, non-generic drugs, and veterinary drugs. Our market research report has extensively covered external factors influencing the parent market growth during the forecast period.
What is the Fastest-Growing Segment in the Autoimmune Drugs Market?
The market share growth by the rheumatoid arthritis segment will be significant during the forecast period. Rheumatoid arthritis is an autoimmune disorder in which the immune system attacks the body's own cells, including the joints, which results in inflammation, pain, and swelling in the joints, mainly in the hands and feet. It is a chronic disease that can ultimately lead to joint deformity and bone erosion.
Get a glance at the market contribution of various segments Request Market Research Report Sample Pdf
The rheumatoid arthritis segment was valued at USD 25,096.41 million in 2017 and continued to grow until 2021. The incidence of rheumatoid arthritis is majorly increasing in the elderly population in several regions. The treatments available for rheumatoid arthritis include conventional DMARDs, small molecule therapeutics, and innovative biologics. Biologics have shown effective results in the long-term management of the disease and are widely prescribed by rheumatologists worldwide. Some of the blockbuster biologics include HUMIRA, Cimzia, SIMPONI, REMICADE, and STELARA. These agents are priced high but have huge worldwide sales, therefore, they significantly contribute to the market size of this segment. Furthermore, initiatives are being undertaken to develop innovative approaches to manage rheumatoid arthritis, and this is likely to propel the market growth. With the expiry of patents for many biologics under this category, the emergence of biosimilars and novel biologics will likely contribute to the gradual increase in market size. Novel treatment approaches are also evolving for this segment. Therefore, these factors are expected to accelerate the growth of this segment which is expected to propel the growth of the market in focus during the forecast period.
Which are the Key Regions for the Autoimmune Drugs Market?
For more insights on the market share of various regions Request Market Research Report Sample Pdf
North America is estimated to contribute 51% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The US is the key country in North America, being a leader in the global market. The availability of advanced technical procedures for disease diagnosis and management, better healthcare awareness, and reimbursement policies for highly prevalent diseases, including autoimmune diseases, has resulted in the US being the biggest market in the Americas. Moreover, the sale of autoimmune drugs, including HUMIRA, Enbrel, REMICADE, STELARA, SIMPONI, ENTYVIO, ORENCIA, and XELJANZ, in the US, is also higher than in other countries.
Factors such as increasing incidence rates of autoimmune diseases and the prevalence of rheumatoid arthritis among the rising aging population in the US are attributed to the increasing market size of North America. Apart from this, there is a robust pipeline of autoimmune drugs in North America, which shows that the market in this region is going to proliferate during the forecast period. Another reason for the growth of the market in North America is the growing involvement of national institutes, including NIH, in developing advanced therapeutics in the autoimmune disease domain. Hence, such factors are expected to drive the growth of the regional market during the forecast period.
The outbreak of COVID-19 in 2020 severely impacted the market in North America. However, with the help of the vaccination drive, the number of cases was reduced in 2021 and stabilized the growth of the regional market in focus owing to the restoration of supply chain activities. Moreover, rescheduling of patient visits to clinics and hospitals and the adoption of autoimmune drugs are expected to boost the growth of the regional market during the forecast period.
Segment Overview
The autoimmune drug market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
- Therapy Area Outlook (USD Million, 2017 - 2027)
- Rheumatoid arthritis
- Multiple sclerosis
- Psoriasis
- Inflammatory bowel disease
- Others
- Distribution Channel Outlook (USD Million, 2017 - 2027)
- Hospital
- Pharmacy
- Drug store/Retail pharmacy
- Online
- Region Outlook (USD Million, 2017 - 2027)
- North America
- The U.S.
- Canada
- Europe
- The U.K.
- Germany
- France
- Rest of Europe
- Asia
- China
- India
- Vietnam
- Others
- Rest of World
- Saudi Arabia
- South Africa
- Brazil
- Others
- North America
|
Autoimmune Drugs Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
173 |
|
Base year |
2022 |
|
Historic period |
2017-2021 |
|
Forecast period |
2023-2027 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 6.39% |
|
Market growth 2023-2027 |
USD 29,314.5 million |
|
Market structure |
Fragmented |
|
YoY growth 2022-2023(%) |
5.87 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 51% |
|
Key countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., AdvaCare Pharma, Amgen Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Cardinal Health Inc., Delphis Pharmaceutical India, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Johnson and Johnson, Medexus Pharmaceuticals Inc., Parvus Therapeutics Inc., Prometheus Laboratories Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Wellona Pharma |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Request Market Research Report Sample Pdf
What are the Key Data Covered in this Autoimmune Drugs Market Research Report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the autoimmune drugs market between 2023 and 2027
- Precise estimation of the size of the autoimmune drugs market size and its contribution to the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the industry across North America, Europe, Asia, and Rest of World (ROW)
- A thorough analysis of the market’s competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of autoimmune drugs market vendors
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapy Area
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2022
- 3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
- 4.1 Global autoimmune drugs market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on Global autoimmune drugs market 2017 - 2021 ($ million)
- 4.2 Therapy area Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Therapy area Segment 2017 - 2021 ($ million)
- 4.3 Distribution channel Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Distribution channel Segment 2017 - 2021 ($ million)
- 4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
- 4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
- 5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Therapy Area
- 6.1 Market segments
- Exhibit 30: Chart on Therapy Area - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Therapy Area - Market share 2022-2027 (%)
- 6.2 Comparison by Therapy Area
- Exhibit 32: Chart on Comparison by Therapy Area
- Exhibit 33: Data Table on Comparison by Therapy Area
- 6.3 Rheumatoid arthritis - Market size and forecast 2022-2027
- Exhibit 34: Chart on Rheumatoid arthritis - Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on Rheumatoid arthritis - Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on Rheumatoid arthritis - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Rheumatoid arthritis - Year-over-year growth 2022-2027 (%)
- 6.4 Multiple sclerosis - Market size and forecast 2022-2027
- Exhibit 38: Chart on Multiple sclerosis - Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Multiple sclerosis - Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Multiple sclerosis - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Multiple sclerosis - Year-over-year growth 2022-2027 (%)
- 6.5 Psoriasis - Market size and forecast 2022-2027
- Exhibit 42: Chart on Psoriasis - Market size and forecast 2022-2027 ($ million)
- Exhibit 43: Data Table on Psoriasis - Market size and forecast 2022-2027 ($ million)
- Exhibit 44: Chart on Psoriasis - Year-over-year growth 2022-2027 (%)
- Exhibit 45: Data Table on Psoriasis - Year-over-year growth 2022-2027 (%)
- 6.6 Inflammatory bowel disease - Market size and forecast 2022-2027
- Exhibit 46: Chart on Inflammatory bowel disease - Market size and forecast 2022-2027 ($ million)
- Exhibit 47: Data Table on Inflammatory bowel disease - Market size and forecast 2022-2027 ($ million)
- Exhibit 48: Chart on Inflammatory bowel disease - Year-over-year growth 2022-2027 (%)
- Exhibit 49: Data Table on Inflammatory bowel disease - Year-over-year growth 2022-2027 (%)
- 6.7 Others - Market size and forecast 2022-2027
- Exhibit 50: Chart on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 51: Data Table on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 52: Chart on Others - Year-over-year growth 2022-2027 (%)
- Exhibit 53: Data Table on Others - Year-over-year growth 2022-2027 (%)
- 6.8 Market opportunity by Therapy Area
- Exhibit 54: Market opportunity by Therapy Area ($ million)
7 Market Segmentation by Distribution Channel
- 7.1 Market segments
- Exhibit 55: Chart on Distribution Channel - Market share 2022-2027 (%)
- Exhibit 56: Data Table on Distribution Channel - Market share 2022-2027 (%)
- 7.2 Comparison by Distribution Channel
- Exhibit 57: Chart on Comparison by Distribution Channel
- Exhibit 58: Data Table on Comparison by Distribution Channel
- 7.3 Hospital - Market size and forecast 2022-2027
- Exhibit 59: Chart on Hospital - Market size and forecast 2022-2027 ($ million)
- Exhibit 60: Data Table on Hospital - Market size and forecast 2022-2027 ($ million)
- Exhibit 61: Chart on Hospital - Year-over-year growth 2022-2027 (%)
- Exhibit 62: Data Table on Hospital - Year-over-year growth 2022-2027 (%)
- 7.4 Pharmacy - Market size and forecast 2022-2027
- Exhibit 63: Chart on Pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 64: Data Table on Pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 65: Chart on Pharmacy - Year-over-year growth 2022-2027 (%)
- Exhibit 66: Data Table on Pharmacy - Year-over-year growth 2022-2027 (%)
- 7.5 Drug store/Retail pharmacy - Market size and forecast 2022-2027
- Exhibit 67: Chart on Drug store/Retail pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 68: Data Table on Drug store/Retail pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 69: Chart on Drug store/Retail pharmacy - Year-over-year growth 2022-2027 (%)
- Exhibit 70: Data Table on Drug store/Retail pharmacy - Year-over-year growth 2022-2027 (%)
- 7.6 Online - Market size and forecast 2022-2027
- Exhibit 71: Chart on Online - Market size and forecast 2022-2027 ($ million)
- Exhibit 72: Data Table on Online - Market size and forecast 2022-2027 ($ million)
- Exhibit 73: Chart on Online - Year-over-year growth 2022-2027 (%)
- Exhibit 74: Data Table on Online - Year-over-year growth 2022-2027 (%)
- 7.7 Market opportunity by Distribution Channel
- Exhibit 75: Market opportunity by Distribution Channel ($ million)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 76: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 77: Chart on Market share by geography 2022-2027 (%)
- Exhibit 78: Data Table on Market share by geography 2022-2027 (%)
- 9.2 Geographic comparison
- Exhibit 79: Chart on Geographic comparison
- Exhibit 80: Data Table on Geographic comparison
- 9.3 North America - Market size and forecast 2022-2027
- Exhibit 81: Chart on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 82: Data Table on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 83: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 84: Data Table on North America - Year-over-year growth 2022-2027 (%)
- 9.4 Europe - Market size and forecast 2022-2027
- Exhibit 85: Chart on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 86: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 87: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 88: Data Table on Europe - Year-over-year growth 2022-2027 (%)
- 9.5 Asia - Market size and forecast 2022-2027
- Exhibit 89: Chart on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 90: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 91: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 92: Data Table on Asia - Year-over-year growth 2022-2027 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 93: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 94: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 95: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 96: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- 9.7 US - Market size and forecast 2022-2027
- Exhibit 97: Chart on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 98: Data Table on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 99: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 100: Data Table on US - Year-over-year growth 2022-2027 (%)
- 9.8 Germany - Market size and forecast 2022-2027
- Exhibit 101: Chart on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 102: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 103: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 104: Data Table on Germany - Year-over-year growth 2022-2027 (%)
- 9.9 Canada - Market size and forecast 2022-2027
- Exhibit 105: Chart on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 106: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 107: Chart on Canada - Year-over-year growth 2022-2027 (%)
- Exhibit 108: Data Table on Canada - Year-over-year growth 2022-2027 (%)
- 9.10 China - Market size and forecast 2022-2027
- Exhibit 109: Chart on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 110: Data Table on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 111: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 112: Data Table on China - Year-over-year growth 2022-2027 (%)
- 9.11 UK - Market size and forecast 2022-2027
- Exhibit 113: Chart on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 114: Data Table on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 115: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 116: Data Table on UK - Year-over-year growth 2022-2027 (%)
- 9.12 Market opportunity by geography
- Exhibit 117: Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 118: Impact of drivers and challenges in 2022 and 2027
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 119: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 120: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 121: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 122: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 123: Matrix on vendor position and classification
- 12.3 AbbVie Inc.
- Exhibit 124: AbbVie Inc. - Overview
- Exhibit 125: AbbVie Inc. - Product / Service
- Exhibit 126: AbbVie Inc. - Key news
- Exhibit 127: AbbVie Inc. - Key offerings
- 12.4 Amgen Inc.
- Exhibit 128: Amgen Inc. - Overview
- Exhibit 129: Amgen Inc. - Product / Service
- Exhibit 130: Amgen Inc. - Key offerings
- 12.5 AstraZeneca Plc
- Exhibit 131: AstraZeneca Plc - Overview
- Exhibit 132: AstraZeneca Plc - Product / Service
- Exhibit 133: AstraZeneca Plc - Key news
- Exhibit 134: AstraZeneca Plc - Key offerings
- 12.6 Bristol Myers Squibb Co.
- Exhibit 135: Bristol Myers Squibb Co. - Overview
- Exhibit 136: Bristol Myers Squibb Co. - Product / Service
- Exhibit 137: Bristol Myers Squibb Co. - Key news
- Exhibit 138: Bristol Myers Squibb Co. - Key offerings
- 12.7 Cardinal Health Inc.
- Exhibit 139: Cardinal Health Inc. - Overview
- Exhibit 140: Cardinal Health Inc. - Business segments
- Exhibit 141: Cardinal Health Inc. - Key news
- Exhibit 142: Cardinal Health Inc. - Key offerings
- Exhibit 143: Cardinal Health Inc. - Segment focus
- 12.8 Delphis Pharmaceutical India
- Exhibit 144: Delphis Pharmaceutical India - Overview
- Exhibit 145: Delphis Pharmaceutical India - Product / Service
- Exhibit 146: Delphis Pharmaceutical India - Key offerings
- 12.9 Eli Lilly and Co.
- Exhibit 147: Eli Lilly and Co. - Overview
- Exhibit 148: Eli Lilly and Co. - Product / Service
- Exhibit 149: Eli Lilly and Co. - Key offerings
- 12.10 F. Hoffmann La Roche Ltd.
- Exhibit 150: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 151: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 152: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 153: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 154: F. Hoffmann La Roche Ltd. - Segment focus
- 12.11 GlaxoSmithKline Plc
- Exhibit 155: GlaxoSmithKline Plc - Overview
- Exhibit 156: GlaxoSmithKline Plc - Business segments
- Exhibit 157: GlaxoSmithKline Plc - Key offerings
- Exhibit 158: GlaxoSmithKline Plc - Segment focus
- 12.12 Hikma Pharmaceuticals Plc
- Exhibit 159: Hikma Pharmaceuticals Plc - Overview
- Exhibit 160: Hikma Pharmaceuticals Plc - Business segments
- Exhibit 161: Hikma Pharmaceuticals Plc - Key offerings
- Exhibit 162: Hikma Pharmaceuticals Plc - Segment focus
- 12.13 Johnson and Johnson
- Exhibit 163: Johnson and Johnson - Overview
- Exhibit 164: Johnson and Johnson - Business segments
- Exhibit 165: Johnson and Johnson - Key news
- Exhibit 166: Johnson and Johnson - Key offerings
- Exhibit 167: Johnson and Johnson - Segment focus
- 12.14 Parvus Therapeutics Inc.
- Exhibit 168: Parvus Therapeutics Inc. - Overview
- Exhibit 169: Parvus Therapeutics Inc. - Product / Service
- Exhibit 170: Parvus Therapeutics Inc. - Key offerings
- 12.15 Sanofi SA
- Exhibit 171: Sanofi SA - Overview
- Exhibit 172: Sanofi SA - Business segments
- Exhibit 173: Sanofi SA - Key news
- Exhibit 174: Sanofi SA - Key offerings
- Exhibit 175: Sanofi SA - Segment focus
- 12.16 Takeda Pharmaceutical Co. Ltd.
- Exhibit 176: Takeda Pharmaceutical Co. Ltd. - Overview
- Exhibit 177: Takeda Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 178: Takeda Pharmaceutical Co. Ltd. - Key news
- Exhibit 179: Takeda Pharmaceutical Co. Ltd. - Key offerings
- 12.17 Teva Pharmaceutical Industries Ltd.
- Exhibit 180: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 181: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 182: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 183: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 184: Teva Pharmaceutical Industries Ltd. - Segment focus
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 185: Inclusions checklist
- Exhibit 186: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 187: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 188: Research methodology
- Exhibit 189: Validation techniques employed for market sizing
- Exhibit 190: Information sources
- 13.5 List of abbreviations
- Exhibit 191: List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
PURCHASE FULL REPORT OF
autoimmune drugs market
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
- Off-the-shelf research reports
- Reports can be tailored to meet the customer's needs
- Trusted by more than 100 fortune 500 organizations
- Information about the market's key drivers, trends, and challenges
- Parent market analysis
- Every week, 50,000 people visit our subscription platform
- Detailed vendors report with competitive landscape
- Covid-19 impact and recovery analysis
- Data on revenue-generating market segments
- Details on the market shares of various regions
- Five-force market analysis